The multiple sclerosis monitoring study: Progress to date

The multiple sclerosis monitoring study: Progress to date

Bibliographic Details
Main Authors:	Cooper, C, Palace, J, Pickin, M, Boggild, M, Nichol, J, Consortium, MS
Format:	Conference item
Published:	2004

Similar Items

The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.
by: Pickin, M, et al.
Published: (2009)

The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the future
by: Pickin, M, et al.
Published: (2009)

The UK Multiple Sclerosis database.
by: Palace, J, et al.
Published: (1999)

The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the future
by: Chilcott James B, et al.
Published: (2009-01-01)

Modifying disability in progressive multiple sclerosis.
by: Palace, J, et al.
Published: (2014)

Modifying disability in progressive multiple sclerosis
by: Palace, J, et al.
Published: (2014)

The UK long-term cost-effectiveness study of disease-modifying therapies in multiple sclerosis: lessons from tire first analysis
by: Palace, J, et al.
Published: (2008)

Modelling natural history for the UK multiple sclerosis risk-sharing scheme
by: Palace, J, et al.
Published: (2013)

EVIDENCE OF SUBCORTICAL ATROPHY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
by: Arun, T, et al.
Published: (2009)

Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator.
by: Boggild, M, et al.
Published: (2009)

Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex
by: Yates, R, et al.
Published: (2017)

Making the diagnosis of multiple sclerosis.
by: Palace, J
Published: (2001)

UK multiple sclerosis risksharing scheme: A new natural history dataset and an improved Markov model
by: Palace, J, et al.
Published: (2014)

New and old treatments for multiple sclerosis.
by: Palace, J
Published: (1998)

UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
by: Palace, J, et al.
Published: (2014)

Guidelines for differential diagnosis of suspected multiple sclerosis.
by: Palace, J
Published: (2009)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
by: Gajofatto A
Published: (2017-11-01)

New treatments and azathioprine in multiple sclerosis.
by: Palace, J, et al.
Published: (1997)

Multiple sclerosis associated with Leber's Hereditary Optic Neuropathy.
by: Palace, J
Published: (2009)

Early clinical predictors of disease progression in relapsing-remitting multiple sclerosis: the Oxford UK cohort
by: Wakerley, B, et al.
Published: (2011)

Interleukin-17 expression in multiple sclerosis
by: Tzartos, J, et al.
Published: (2006)

DIRECT COMPARISON OF MULTIPLE NONLESIONAL IMAGING MEASURES TO ASSESS THEIR POWER TO MEASURE TREATMENT EFFECTS OVER 1 YEAR IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
by: Arun, T, et al.
Published: (2010)

AMILORIDE TREATMENT AMELIORATES MRI SURROGATE MARKERS OF NEURODEGENERATION IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
by: Arun, T, et al.
Published: (2012)

Thalamic neurodegeneration in multiple sclerosis.
by: Cifelli, A, et al.
Published: (2002)

A decade of data for the uk multiple sclerosis risk-sharing scheme.
by: Duddy, M, et al.
Published: (2013)

COMPARING MRI MEASURES OF MYELIN INTEGRITY AS SURROGATE MARKERS FOR THE CLINICAL EXPRESSION OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
by: Matthews, L, et al.
Published: (2010)

ASIC1 Blockade in Primary Progressive Multiple Sclerosis: Evidence of Neuroprotection with Amiloride
by: Arun, T, et al.
Published: (2013)

Modafinil for multiple sclerosis fatigue: does it work?
by: Littleton, E, et al.
Published: (2010)

Multiple sclerosis lesions: insights from imaging techniques.
by: Tomassini, V, et al.
Published: (2009)

Running a mitoxantrone service for multiple sclerosis
by: Craner, M, et al.
Published: (2006)

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
by: Carnero Contentti E, et al.
Published: (2022-10-01)

An approach to the identification of targets of autoantibodies in multiple sclerosis
by: Littleton, E, et al.
Published: (2004)

Grey matter neuronal loss in multiple sclerosis
by: Cifelli, A, et al.
Published: (2002)

Reduced EDSS progression in multiple sclerosis patients treated with modafinil for three years or more compared to matched untreated subjects
by: Bibani, R, et al.
Published: (2012)

Reduced EDSS progression in multiple sclerosis patients treated with modafinil for three years or more compared to matched untreated subjects
by: Bibani, R, et al.
Published: (2012)

The pathogenesis of multiple sclerosis: is it really a primary inflammatory process?
by: Maggs, F, et al.
Published: (2004)

Neocortical neuronal, synaptic, and glial loss in multiple sclerosis.
by: Wegner, C, et al.
Published: (2006)

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
by: Parry, A, et al.
Published: (2003)

beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis
by: Parry, A, et al.
Published: (2002)

Towards defining antigenic targets for antibodies in multiple sclerosis
by: Littleton, E, et al.
Published: (2006)